This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Despite worried hand-wringing over a potential slowdown in FDA approvals under the new administration, the agency has been giving the go-ahead to drugs at a near record-setting clip. Meanwhile, the decision-making production has come during a major upheaval inside the FDA.
Jacqueline Durett Few times in the evolution of a pharmaceutical company are as exciting as during the flurry of launch readiness activities focused on bringing a new drug to market. According to a Deloitte Insights report, “Rethinking MarketAccess,” at least 34% of new drugs fall into that category. The takeaway?
Created by and for patient organizations over 100 years ago, the NHC brings diverse organizations together to forge consensus and drive patient-centered health policy. We promote increased access to affordable, high-value, equitable, and sustainable health care. percent market basket increase offset by a 0.8 percent to 0.3
Cliff Wilson was appointed market president and CEO of Albuquerque, N.M.-based Wyatt Brieser was appointed CEO of Hammond-Henry Hospital, a critical access hospital in Geneseo, Ill. will retire in August after 17 years at the helm. based Lifepoint Health’s Central Kentucky market president and CEO of Georgetown (Ky.)
It is undeniable that 2020 was a particularly challenging year to launch non-COVID innovative prescription medicines. These are innovative prescription medicine molecules (small molecules and biologics) that are entering a given country market for the first time. We measured the pandemic impact on the launch of NAS at four levels.
1 Timeline for tariff implementation and trade policy volatility During a cabinet meeting, he noted that these fees would not go into effect immediately, but rather, in a year or year and a half. President Trump noted that import taxes on pharmaceuticals of up to 200% could come forthcoming.
To be honest, for many years, I was quite skeptical that it could be done without taking external thyroid hormones. But over the years, Ive worked with thousands of people with Hashimotos and hypothyroidism and have kept an eye on emerging research and trends.
As the pharma market continues to grow and branch out, major players aim to expand and diversify to remain at the top of the game. There was an increase in the number of M&A deals announced in 2024 compared to the previous year but strategic alliances volume fell. So, lets examine the drivers of M&As in detail.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content